Science Advances · 16 October 2026 · From issue 53
Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
A low dose immune drug combo matched higher doses but caused fewer side effects in prostate cancer.
Apostolia M. Tsimberidou, Christopher R. Cabanski et al.
Integrity screen: passed (3 checks) Checked 20 October 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue